Global Telisotuzumab Vedotin Market Size, Share & Trends Analysis Report By Indication (Non-Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer, Other Solid Tumors), By Therapy Line (First-Line, Second-Line, Third-Line & Beyond), By Biomarker Status (c-Met High Overexpression, c-Met Intermediate Expression, MET Gene Amplification, MET Exon 14 Skipping), By Combination Regimen (Monotherapy, Combination with Immunotherapy, Combination with Targeted Therapy), By End-User (Hospitals & Cancer Centers, Specialty Oncology Clinics, Academic Medical Centers, Ambulatory Surgical Centers), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Oncology Group Purchasing Organizations, Mail-Order Pharmacies), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) - Forecasts, 2026-2034

Table of Contents

1. Introduction
1.1. Market Introduction
1.2. Research Methodology
1.3. Market Estimation Methodology
1.4. Executive Summary
1.5. Product Overview: Telisotuzumab Vedotin
1.6. Antibody-Drug Conjugate (ADC) Ecosystem Overview
1.7. c-Met Biology & Precision Oncology Landscape
1.8. Market Scope & Segmentation
1.9. Key Findings Snapshot

2. Global Telisotuzumab Vedotin Market Overview

2.1. Market Outlook
2.2. Market Size & Forecast (2022-2034)
2.3. Value Chain Analysis
2.4. Regulatory Landscape Assessment
2.5. Reimbursement & Market Access Overview
2.6. Biomarker Testing Infrastructure Analysis
2.7. Clinical Development Landscape
2.8. Porter’s Five Forces Analysis
2.9. PESTLE Analysis

3. Market Dynamics

3.1. Market Drivers

3.1.1. Significant Unmet Need in c-Met Overexpressing Solid Tumors
3.1.2. Expanding Regulatory Approvals and Global Market Access
3.1.3. Growing Adoption of Precision Oncology Approaches
3.1.4. Increasing Companion Diagnostic Utilization

3.2. Market Restraints

3.2.1. Premium Therapy Pricing and Reimbursement Challenges
3.2.2. Biomarker Testing Accessibility Limitations
3.2.3. Complex Regulatory and Market Access Requirements

3.3. Market Opportunities

3.3.1. Expansion into Combination Therapy Regimens
3.3.2. Earlier-Line Treatment Opportunities
3.3.3. Broadening Applications Across Multiple Solid Tumors
3.3.4. Emerging Market Penetration Potential

3.4. Emerging Trends

3.4.1. AI-Driven Digital Pathology Integration
3.4.2. Liquid Biopsy-Based c-Met Testing
3.4.3. Personalized Biomarker-Guided Treatment Selection
3.4.4. ADC Innovation and Next-Generation Payload Development

4. Global Telisotuzumab Vedotin Market Analysis, By Indication

4.1. Overview
4.2. Non-Small Cell Lung Cancer (NSCLC)
4.3. Gastric & Gastroesophageal Junction Cancer
4.4. Colorectal Cancer
4.5. Hepatocellular Carcinoma
4.6. Head & Neck Squamous Cell Carcinoma
4.7. Other Solid Tumors

5. Global Telisotuzumab Vedotin Market Analysis, By Therapy Line

5.1. Overview
5.2. First-Line Therapy
5.3. Second-Line Therapy
5.4. Third-Line & Beyond Therapy

6. Global Telisotuzumab Vedotin Market Analysis, By Biomarker Status

6.1. Overview
6.2. c-Met High Overexpression (IHC 3+)
6.3. c-Met Intermediate Expression (IHC 2+)
6.4. MET Gene Amplification
6.5. MET Exon 14 Skipping

7. Global Telisotuzumab Vedotin Market Analysis, By Combination Regimen

7.1. Overview
7.2. Monotherapy
7.3. Combination with PD-1/PD-L1 Inhibitors
7.4. Combination with EGFR Inhibitors
7.5. Combination with Chemotherapy
7.6. Other Targeted Combinations

8. Global Telisotuzumab Vedotin Market Analysis, By End-User

8.1. Overview
8.2. Hospitals & Cancer Centers
8.3. Specialty Oncology Clinics
8.4. Academic Medical Centers
8.5. Ambulatory Surgical Centers

9. Global Telisotuzumab Vedotin Market Analysis, By Distribution Channel

9.1. Overview
9.2. Hospital Pharmacies
9.3. Specialty Pharmacies
9.4. Oncology Group Purchasing Organizations
9.5. Mail-Order Pharmacies

10. Global Telisotuzumab Vedotin Market Analysis, By Region

10.1. North America

10.1.1. United States
10.1.2. Canada
10.1.3. Mexico

10.2. Europe

10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Netherlands
10.2.7. Rest of Europe

10.3. Asia Pacific

10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia Pacific

10.4. Middle East & Africa

10.4.1. Saudi Arabia
10.4.2. UAE
10.4.3. South Africa
10.4.4. Rest of Middle East & Africa

10.5. Latin America

10.5.1. Brazil
10.5.2. Argentina
10.5.3. Rest of Latin America

11. Competitive Landscape

11.1. Market Share Analysis
11.2. Competitive Benchmarking
11.3. Strategic Positioning Analysis
11.4. ADC Competitive Landscape Assessment
11.5. Companion Diagnostics Ecosystem Analysis
11.6. Partnership, Licensing & Collaboration Analysis
11.7. Mergers & Acquisitions Activity

12. Company Profiles

12.1. Merck & Co., Inc.
12.2. Daiichi Sankyo Co., Ltd.
12.3. Partner Therapeutics, Inc.
12.4. Roche Diagnostics
12.5. Agilent Technologies, Inc.
12.6. Thermo Fisher Scientific Inc.
12.7. Guardant Health, Inc.
12.8. Foundation Medicine, Inc.
12.9. NeoGenomics Laboratories, Inc.
12.10. Exact Sciences Corporation

13. Biomarker & Diagnostic Infrastructure Analysis

13.1. Global c-Met Testing Market Overview
13.2. Companion Diagnostic Adoption Trends
13.3. Immunohistochemistry Testing Landscape
13.4. Liquid Biopsy Adoption Analysis
13.5. AI-Powered Digital Pathology Assessment
13.6. Laboratory Network Expansion Analysis

14. Clinical Pipeline & Innovation Analysis

14.1. Telisotuzumab Vedotin Development Timeline
14.2. Ongoing Clinical Trials Overview
14.3. Combination Therapy Pipeline Assessment
14.4. Future Indication Expansion Opportunities
14.5. Next-Generation c-Met Targeting Technologies
14.6. Regulatory Milestones & Approval Outlook

15. Key Strategic Recommendations

15.1. Growth Opportunity Assessment
15.2. Commercialization Strategy Analysis
15.3. Market Entry & Expansion Roadmap
15.4. Investment Opportunity Assessment
15.5. Future Market Outlook (2026-2034)

16. Appendix

16.1. Abbreviations
16.2. Sources & References
16.3. Assumptions and Limitations
16.4. About the Research Firm